Coherus Oncology (NASDAQ:CHRS) Issues Quarterly Earnings Results

Coherus Oncology (NASDAQ:CHRS) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.05, FiscalAI reports. Coherus Oncology had a negative return on equity of 198.90% and a net margin of 397.30%.The business had revenue of $14.31 million for the quarter, compared to analyst estimates of $14.41 million.

Here are the key takeaways from Coherus Oncology’s conference call:

• LOQTORZI sales increased 15% quarter over quarter to $13.6 million, supported by the highest number of new patient starts since launch, lower discontinuations, and gradually improving treatment duration. Management reiterated its 2026 revenue outlook of $57 million to $62 million and expects average quarterly growth of 10% to 15%.
• Tagmokitug studies in head and neck cancer and colorectal cancer, along with the casdozokitug first-line HCC study, have completed enrollment. Early, immature data in PD-1-resistant head and neck cancer showed manageable safety and signs of activity, potentially enriched among HPV-positive patients and those with higher TIRI scores; a formal update is expected in October.
• Casdozokitug HCC data are expected in the fourth quarter, but the study remains relatively immature, with only about half of patients having received three scans. Management said it may not need to wait for overall-survival data to decide on a potential Phase III program, while emphasizing response durability, clinical benefit rate, ctDNA, and IL-27 biomarkers.
• Cash, cash equivalents, and investments declined to $105.3 million from $167 million in the prior quarter, primarily because of $39 million in transition-service-agreement obligations. The company said it remains funded through key 2026–2027 readouts, but the $37.5 million Q2 UDENYCA divestiture milestone was not achieved, subject to final buyer-result adjustments.
• Continuing-operations R&D and SG&A expenses fell year over year, and the company expects full-year 2026 operating expenses of $170 million to $175 million. Legacy biosimilar liabilities also declined substantially and are expected to be largely settled by year-end.

Coherus Oncology Stock Down 2.0%

Shares of Coherus Oncology stock traded down $0.03 on Wednesday, hitting $1.45. The company had a trading volume of 992,580 shares, compared to its average volume of 599,672. Coherus Oncology has a 1 year low of $0.81 and a 1 year high of $2.62. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.52 and a current ratio of 1.56. The stock has a 50 day moving average of $1.47 and a 200-day moving average of $1.67. The stock has a market capitalization of $223.66 million, a price-to-earnings ratio of 0.87 and a beta of 0.98.

Institutional Investors Weigh In On Coherus Oncology

Several institutional investors have recently bought and sold shares of the stock. Quarry LP purchased a new stake in Coherus Oncology in the 3rd quarter valued at $26,000. Blair William & Co. IL bought a new stake in shares of Coherus Oncology in the 4th quarter worth $27,000. BNP Paribas Financial Markets grew its stake in shares of Coherus Oncology by 108.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 13,832 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of Coherus Oncology in the third quarter valued at about $59,000. Finally, Focus Partners Wealth purchased a new stake in shares of Coherus Oncology in the third quarter valued at about $70,000. Institutional investors own 72.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CHRS. Weiss Ratings raised Coherus Oncology from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 13th. Guggenheim assumed coverage on shares of Coherus Oncology in a research report on Monday, May 11th. They issued a “buy” rating and a $12.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.67.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.